{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:50:26Z","timestamp":1794397826290,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olanzapine is an atypical antipsychotic that has affinity for many central nervous system receptors. Its efficacy is supported by several studies in the prevention and treatment of chemotherapy-induced nausea and vomiting. No recommendations exist on the antiemetic use of olanzapine in the palliative care setting. The aim of this work is to complete the initial work of Fonte et al. published in 2015, to determine whether the literature supports the use of olanzapine as an antiemetic in palliative situations and, in practice, to propose a therapeutic schema adapted to the palliative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review of the literature according to the PRISMA criteria. We searched the PubMed, Cochrane, RefDoc, EMBase databases and the gray literature databases. The bibliographic search was conducted between November 2016 and August 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen articles were included: 2 case studies, 3 case series, 3 retrospective studies, 2 prospective studies, 2 literature reviews. All studies concluded on the efficacy of olanzapine as an antiemetic in the palliative care setting. No serious adverse effects were reported. Based on the data from the literature review, we propose a therapeutic scheme adapted to the palliative care context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Action of olanzapine on many receptors and its tolerance profile make it an interesting antiemetic treatment in palliative medicine. But to date, studies are scarce and have a low statistical power. Further investigation is therefore needed to determine the benefit of this treatment in palliative care patients, compared to usual treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12904-020-00559-4","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T11:04:14Z","timestamp":1587553454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature"],"prefix":"10.1186","volume":"19","author":[{"given":"G.","family":"Saudemont","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Prod\u2019Homme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Villet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"559_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1099-1611(200001\/02)9:1<84::AID-PON440>3.0.CO;2-T","volume":"9","author":"W Pirl","year":"2000","unstructured":"Pirl W, Roth A. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment - a case report. Psychooncology. 2000;9:84\u20137.","journal-title":"Psychooncology."},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejphar.2013.09.072","volume":"722","author":"PLR Andrews","year":"2014","unstructured":"Andrews PLR, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108\u201321.","journal-title":"Eur J Pharmacol"},{"key":"559_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","volume":"24","author":"R Chow","year":"2016","unstructured":"Chow R, Chiu L, Navari R, Passik S, Chiu N, Popovic M, et al. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016;24:1001\u20138.","journal-title":"Support Care Cancer"},{"key":"559_CR4","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016;24:2381\u201392.","journal-title":"Support Care Cancer"},{"key":"559_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21:1655\u201363.","journal-title":"Support Care Cancer"},{"key":"559_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00520-014-2138-y","volume":"22","author":"CM Hocking","year":"2014","unstructured":"Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22:1143\u201351.","journal-title":"Support Care Cancer"},{"key":"559_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","volume":"112","author":"J Yoodee","year":"2017","unstructured":"Yoodee J, Permsuwan U, Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;112:113\u201325.","journal-title":"Crit Rev Oncol Hematol"},{"key":"559_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/phar.1703","volume":"36","author":"DL DeRemer","year":"2016","unstructured":"DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi AS. Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting. Pharmacother. 2016;36:218\u201329.","journal-title":"Pharmacother."},{"key":"559_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26:1081\u201390.","journal-title":"Ann Oncol"},{"key":"559_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.02.010","volume":"95","author":"C Fonte","year":"2015","unstructured":"Fonte C, Fatigoni S, Roila F. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol Hematol. 2015;95:214\u201321.","journal-title":"Crit Rev Oncol Hematol"},{"key":"559_CR11","first-page":"1","volume":"12","author":"N Franck","year":"2015","unstructured":"Franck N, Fromager F, Thibaut F. Pharmacologie et mode d\u2019action des antipsychotiques. EMC \u2013 Psychiatr. 2015;12:1\u201317.","journal-title":"EMC \u2013 Psychiatr"},{"key":"559_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1345\/aph.17215","volume":"33","author":"JS Markowitz","year":"1999","unstructured":"Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999;33:73\u201385.","journal-title":"Ann Pharmacother"},{"key":"559_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1049909112441241","volume":"30","author":"E Prommer","year":"2013","unstructured":"Prommer E. Olanzapine: Palliative Medicine Update. Am J Hosp Palliat Med. 2013;30:75\u201382.","journal-title":"Am J Hosp Palliat Med"},{"key":"559_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"F Bymaster","year":"1996","unstructured":"Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87\u201396.","journal-title":"Neuropsychopharmacology."},{"key":"559_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0885-3924(98)00128-6","volume":"17","author":"SD Passik","year":"1999","unstructured":"Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manag. 1999;17:219\u201323.","journal-title":"J Pain Symptom Manag"},{"key":"559_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1017\/S1478951514001059","volume":"13","author":"S Boettger","year":"2015","unstructured":"Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015;13:1079\u201385.","journal-title":"Palliat Support Care"},{"key":"559_CR17","unstructured":"VIDAL Olanzapine. 2013. https:\/\/www.vidal.fr\/substances\/17677\/olanzapine. Accessed 11 sept 2017."},{"key":"559_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"A Lehman","year":"2004","unstructured":"Lehman A, Lieberman J, Dixon L, MacGlashan T, Miller A, Perkins D, et al. Practice guidelines for treatment of patients with schizophrenia - Second edition. Am J Psychiatr. 2004;161:1\u201356.","journal-title":"Am J Psychiatr"},{"key":"559_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/acem.12842","volume":"23","author":"ML Martel","year":"2016","unstructured":"Martel ML, Klein LR, Rivard RL, Cole JB. A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department. Acad Emerg Med. 2016;23:29\u201335.","journal-title":"Acad Emerg Med"},{"key":"559_CR20","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jpainsymman.2010.02.017","volume":"40","author":"A Elsayem","year":"2010","unstructured":"Elsayem A, Bush SH, Munsell MF, Curry E, Calderon BB, Paraskevopoulos T, et al. Subcutaneous Olanzapine for Hyperactive or Mixed Delirium in Patients with Advanced Cancer: A Preliminary Study. J Pain Symptom Manag. 2010;40:774\u201382.","journal-title":"J Pain Symptom Manag"},{"key":"559_CR21","first-page":"1","volume":"5","author":"AEI Nagwa","year":"2015","unstructured":"Nagwa AEI. Nausea and Vomiting in Cancer Patients: Topic Review. J Palliat Care Med. 2015;5:1.","journal-title":"J Palliat Care Med"},{"key":"559_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11864-020-0704-8","volume":"21","author":"RM Navari","year":"2020","unstructured":"Navari RM. Nausea and Vomiting in Advanced Cancer. Curr Treat Options in Oncol. 2020;21:14.","journal-title":"Curr Treat Options in Oncol"},{"key":"559_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0871-6","volume":"22","author":"RJ Wickham","year":"2020","unstructured":"Wickham RJ. Nausea and Vomiting: a Palliative Care Imperative. Curr Oncol Rep. 2020;22:1.","journal-title":"Curr Oncol Rep"},{"key":"559_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.kine.2014.11.004","volume":"15","author":"M Gedda","year":"2015","unstructured":"Gedda M. Traduction fran\u00e7aise des lignes directrices PRISMA pour l\u2019\u00e9criture et la lecture des revues syst\u00e9matiques et des m\u00e9ta-analyses. Kin\u00e9sith\u00e9rapie Rev. 2015;15:39\u201344.","journal-title":"Kin\u00e9sith\u00e9rapie Rev"},{"key":"559_CR25","unstructured":"INSERM. Le MeSH Bilingue. 2017. http:\/\/mesh.inserm.fr\/FrenchMesh. Accessed 9 Sept 2017."},{"key":"559_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/1049909110369532","volume":"27","author":"N Licup","year":"2010","unstructured":"Licup N, Baumrucker S. Olanzapine for Nausea and Vomiting. Am J Hosp Palliat Med. 2010;27:432\u20134.","journal-title":"Am J Hosp Palliat Med"},{"key":"559_CR27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1089\/jpm.2016.0220","volume":"19","author":"M Felton","year":"2016","unstructured":"Felton M, Weinberg R, Pruskowski J. Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315. J Palliat Med. 2016;19:1224\u20135.","journal-title":"J Palliat Med"},{"key":"559_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"SD Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23:526\u201332.","journal-title":"J Pain Symptom Manag"},{"key":"559_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1089\/jpm.2015.0224","volume":"19","author":"D MacKintosh","year":"2016","unstructured":"MacKintosh D. Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series. J Palliat Med. 2016;19:87\u201390.","journal-title":"J Palliat Med"},{"key":"559_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T. Olanzapine for the Relief of Nausea in Patients With Advanced Cancer and Incomplete Bowel Obstruction. J Pain Symptom Manag. 2012;44:604\u20137.","journal-title":"J Pain Symptom Manag"},{"key":"559_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/jpm.2014.0030","volume":"17","author":"SR Atkinson","year":"2014","unstructured":"Atkinson SR. Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy. J Palliat Med. 2014;17:503\u20134.","journal-title":"J Palliat Med"},{"key":"559_CR32","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00520-016-3101-x","volume":"24","author":"K Kaneishi","year":"2016","unstructured":"Kaneishi K, Nishimura K, Sakurai N, Imai K, Matsuo N, Takahashi N, et al. Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan. Support Care Cancer. 2016;24:2393\u20135.","journal-title":"Support Care Cancer"},{"key":"559_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/109662103764978506","volume":"6","author":"WC Jackson","year":"2003","unstructured":"Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6:251\u20135.","journal-title":"J Palliat Med"},{"key":"559_CR34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0885-3924(03)00143-X","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in Advanced Cancer. J Pain Symptom Manag. 2003;25:578\u201382.","journal-title":"J Pain Symptom Manag"},{"key":"559_CR35","first-page":"214","volume":"23","author":"S Atreya","year":"2016","unstructured":"Atreya S, Datta SS. Olanzapine for refractory nausea and vomiting in patients with advanced malignancy. Eur J Palliat Care. 2016;23:214\u20138.","journal-title":"Eur J Palliat Care"},{"key":"559_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000358044","volume":"8","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Komuro K, Ohara K. Olanzapine and Betamethasone Are Effective for the Treatment of Nausea and Vomiting due to Metastatic Brain Tumors of Rectal Cancer. Case Rep Gastroenterol. 2014;8:13\u20137.","journal-title":"Case Rep Gastroenterol"},{"key":"559_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/15360288.2015.1035831","volume":"29","author":"M Langley-DeGroot","year":"2015","unstructured":"Langley-DeGroot M, Ma JD, Hirst J, Roeland EJ. Olanzapine in the Treatment of Refractory Nausea and Vomiting: A Case Report and Review of the Literature. J Pain Palliat Care Pharmacother. 2015;29:148\u201352.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"559_CR38","unstructured":"VIDAL Haloperidol. 2013. https:\/\/www.vidal.fr\/substances\/1726\/haloperidol. Accessed 11 sept 2017."},{"key":"559_CR39","first-page":"5","volume":"11","author":"G Laval","year":"2012","unstructured":"Laval G, Marcelin-Benazech B, Arvieux C, Chauvenet L, Copel L, Durand A, et al. Traitement symptomatique de l\u2019occlusion intestinale sur carcinose p\u00e9riton\u00e9ale\u00a0: Recommandations de bonnes pratiques cliniques. Med Palliat. 2012;11:5\u201324.","journal-title":"Med Palliat"},{"key":"559_CR40","unstructured":"Cochois I. HALDOL 5 mg\/ml solution injectable (halop\u00e9ridol)\u00a0: suppression de la voie d\u2019administration intraveineuse. VIDAL. 2011. https:\/\/www.vidal.fr\/actualites\/11688\/haldol_5_mg_ml_solution_injectable_haloperidol_suppression_de_la_voie_d_administration_intraveineuse. Accessed 27 Aug 2017."},{"key":"559_CR41","unstructured":"ANSM (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9). Suppression de la voie d\u2019administration par Intra-Veineuse de Haldol\u00ae 5 mg\/ml, solution injectable en ampoule (halop\u00e9ridol) - Lettre aux professionnels de sant\u00e9 (16\/02\/2011). https:\/\/ansm.sante.fr\/S-informer\/Informations-de-securite-Lettres-aux-professionnels-de-sante\/Haldol-R-5-mg-ml-solution-injectable-en-ampoule-haloperidol-Laboratoire-Janssen-Cilag-Suppression-de-la-voie-d-administration-par-Intra-Veineuse. Accessed 16 Apr 2020."},{"key":"559_CR42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jen.2004.07.033","volume":"30","author":"R Bergstrom","year":"2004","unstructured":"Bergstrom R. Rapid Onset of Absorption with Olanzapine Orally Disintegrating Tablets. J Emerg Nurs. 2004;30:416\u20137.","journal-title":"J Emerg Nurs"},{"key":"559_CR43","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/0091270005283839","volume":"46","author":"JS Markowitz","year":"2006","unstructured":"Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang J-S, Zhu H-J, et al. Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers. J Clin Pharmacol. 2006;46:164\u201371.","journal-title":"J Clin Pharmacol"},{"key":"559_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/PPA.S27344","volume":"6","author":"B Montgomery","year":"2012","unstructured":"Montgomery B. Treuer, Karagianis, Ascher-Svanum H, Harrison. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence. 2012;6:109\u201325.","journal-title":"Patient Prefer Adherence"},{"key":"559_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40780-016-0055-6","volume":"2","author":"K Matsumoto","year":"2016","unstructured":"Matsumoto K, Kimura S, Takahashi K, Yokoyama Y, Miyazawa M, Kushibiki S, et al. Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation. J Pharm Health Care Sci. 2016;2:20.","journal-title":"J Pharm Health Care Sci"},{"key":"559_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF02311185","volume":"120","author":"BL Roth","year":"1995","unstructured":"Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology. 1995;120:365\u20138.","journal-title":"Psychopharmacology"},{"key":"559_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/104990910101800212","volume":"18","author":"MP Davis","year":"2001","unstructured":"Davis MP, Dickerson ED. Olanzapine: another psychotropic? Am J Hosp Palliat Med. 2001;18:129\u201332.","journal-title":"Am J Hosp Palliat Med"},{"key":"559_CR48","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2146\/ajhp060414","volume":"64","author":"LA Kroon","year":"2007","unstructured":"Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007;64:1917\u201321.","journal-title":"Am J Health Syst Pharm"},{"key":"559_CR49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3917\/inka.074.0095","volume":"22","author":"M Beauverd","year":"2007","unstructured":"Beauverd M, Pautex S, Pereira J. Place des neuroleptiques atypiques dans la prise en charge du delirium et des naus\u00e9es chez le patient palliatif. InfoKara. 2007;22:95\u2013103.","journal-title":"InfoKara."},{"key":"559_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2354.2006.00760.x","volume":"16","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care. 2007;16:351\u20134.","journal-title":"Eur J Cancer Care"},{"key":"559_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/956785","volume":"2015","author":"M Abe","year":"2015","unstructured":"Abe M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N, et al. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy. Biomed Res Int. 2015;2015:1\u20136.","journal-title":"Biomed Res Int"},{"key":"559_CR52","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1345\/aph.17216","volume":"33","author":"CS Brown","year":"1999","unstructured":"Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II adverse effects, drug interactions, and costs. Ann Pharmacother. 1999;33:210\u20137.","journal-title":"Ann Pharmacother"},{"key":"559_CR53","unstructured":"ANSM. Risque de mortalit\u00e9 et d\u2019accidents vasculaires c\u00e9r\u00e9braux chez les patients \u00e2g\u00e9s atteints de d\u00e9mence trait\u00e9s par olanzapine (Zyprexa\u00ae, Zyprexa Velotab\u00ae) pour des troubles psychotiques et\/ou troubles du comportement. 2004. https:\/\/www.ansm.sante.fr\/S-informer\/Informations-de-securite-Lettres-aux-professionnels-de-sante\/Risque-de-mortalite-et-d-accidents-vasculaires-cerebraux-chez-les-patients-ages-atteints-de-demence-traites-par-olanzapine-Zyprexa-R-Zyprexa-Velotab-R-pour-des-troubles-psychotiques-et-ou-troubles-du-comportement. Accessed 3 Aug 2018."},{"key":"559_CR54","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3917\/spub.145.0655","volume":"26","author":"V Zaugg","year":"2014","unstructured":"Zaugg V, Savoldelli V, Sabatier B, Durieux P. Am\u00e9liorer les pratiques et l\u2019organisation des soins: m\u00e9thodologie des revues syst\u00e9matiques. Sant\u00e9 Publique. 2014;26:655\u201367.","journal-title":"Sant\u00e9 Publique"},{"key":"559_CR55","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/jpm.2017.0159","volume":"21","author":"M Digges","year":"2018","unstructured":"Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, Sinnarajah A, Currow DC, Johnson MJ. Pharmacovigilance in Hospice\/Palliative Care: Net Effect of Haloperidol for Nausea or Vomiting. J Palliat Med. 2018;21:37\u201343.","journal-title":"J Palliat Med"},{"key":"559_CR56","doi-asserted-by":"crossref","unstructured":"Navari RM. A placebo controlled, randomized, double-blinded trial of olanzapine for the treatment of chronic nausea and\/or vomiting, unrelated to chemotherapy\/radiation. JCO 2019;37(31_suppl):118.","DOI":"10.1200\/JCO.2019.37.31_suppl.118"},{"key":"559_CR57","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00520-018-4623-1","volume":"8","author":"S Harder","year":"2019","unstructured":"Harder S, et al. The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment. Support Care Cancer. 2019;8:3071\u201380.","journal-title":"Support Care Cancer"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-020-00559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12904-020-00559-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-020-00559-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T21:45:40Z","timestamp":1666388740000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-020-00559-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1186\/s12904-020-00559-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18206\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18206\/v1","asserted-by":"object"}]},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Data collected from the medical prescription software are already declared to the French national commission for the use of computer data (Commission Nationale Informatique et Libert\u00e9, CNIL) by the Oscar Lambret center, so there was no need for additional authorization about ethics approval and consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}